CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report released on Tuesday morning,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Price Performance

NASDAQ CLGN opened at $3.69 on Tuesday. The stock’s 50-day moving average is $3.89 and its 200-day moving average is $4.33. CollPlant Biotechnologies has a one year low of $3.24 and a one year high of $6.75. The firm has a market cap of $42.19 million, a P/E ratio of -2.39 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter last year, the business earned ($0.38) earnings per share. Equities analysts anticipate that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Hedge Funds Weigh In On CollPlant Biotechnologies

A number of institutional investors have recently added to or reduced their stakes in the company. Benjamin Edwards Inc. acquired a new stake in CollPlant Biotechnologies in the third quarter valued at $112,000. AMH Equity Ltd lifted its stake in CollPlant Biotechnologies by 17.4% in the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC grew its holdings in CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the period. 21.69% of the stock is currently owned by institutional investors and hedge funds.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.